We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+4.9%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$34M
Cap. Flow
% of AUM
12.86%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DT Midstream
DTM
|
+$1.85M |
| 2 |
Delek US
DK
|
+$898K |
| 3 |
ScottsMiracle-Gro
SMG
|
+$843K |
| 4 |
Valero Energy
VLO
|
+$783K |
| 5 |
FMC
FMC
|
+$709K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COR
Coresite Realty Corporation
COR
|
+$1.67M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$551K |
| 4 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$448K |
| 5 |
Travere Therapeutics
TVTX
|
+$434K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGMO
301
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $167K | 0.06% |
22,227
+4,141
| +23% | +$36K |
|
302
Shattuck Labs
STTK
$651M
| $167K | 0.06% |
19,648
+12,186
| +163% | +$168K |
|
|
TVRD
303
Tvardi Therapeutics
TVRD
$22.9M
| $167K | 0.06% |
381
-30
| -7% | -$15.1K |
|
304
BioXcel Therapeutics
BTAI
$26.1M
| $166K | 0.06% |
510
+163
| +47% | +$69.9K |
|
305
Codexis
CDXS
$161M
| $166K | 0.06% |
5,315
-4,550
| -46% | -$150K |
|
|
ARNA
306
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $166K | 0.06% |
1,785
-1,393
| -44% | -$91.8K |
|
307
Atara Biotherapeutics
ATRA
$70.4M
| $165K | 0.06% |
418
-162
| -28% | -$68.2K |
|
308
GH Research
GHRS
$1.92B
| $165K | 0.06% |
+7,086
| New | +$156K |
|
|
KALV
309
DELISTED
KalVista Pharmaceuticals
KALV
| $165K | 0.06% |
12,482
+4,988
| +67% | +$79.4K |
|
310
PMV Pharmaceuticals
PMVP
$58.7M
| $165K | 0.06% |
7,151
+922
| +15% | +$22.3K |
|
|
NGM
311
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $165K | 0.06% |
9,301
-1,623
| -15% | -$31.1K |
|
|
CLVS
312
DELISTED
Clovis Oncology, Inc.
CLVS
| $165K | 0.06% |
60,836
+24,426
| +67% | +$90.3K |
|
313
Invivyd
IVVD
$175M
| $164K | 0.06% |
+22,625
| New | +$588K |
|
314
Lexicon Pharmaceuticals
LXRX
$1.04B
| $164K | 0.06% |
41,584
-2,794
| -6% | -$13.6K |
|
|
GTHX
315
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $164K | 0.06% |
16,088
+6,745
| +72% | +$86K |
|
316
AC Immune
ACIU
$236M
| $163K | 0.06% |
32,852
+4,158
| +14% | +$24.2K |
|
317
Cullinan Oncology
CGEM
$1.07B
| $163K | 0.06% |
10,536
+3,611
| +52% | +$72K |
|
318
Krystal Biotech
KRYS
$10.7B
| $163K | 0.06% |
2,336
-952
| -29% | -$55.4K |
|
319
Scholar Rock
SRRK
$5.92B
| $163K | 0.06% |
6,578
-46
| -0.7% | -$1.27K |
|
320
Denali Therapeutics
DNLI
$3.82B
| $162K | 0.06% |
3,633
+803
| +28% | +$38K |
|
321
MacroGenics
MGNX
$245M
| $162K | 0.06% |
10,120
-93
| -0.9% | -$1.75K |
|
322
Replimune Group
REPL
$449M
| $162K | 0.06% |
5,986
-148
| -2% | -$4.43K |
|
323
Alector
ALEC
$169M
| $161K | 0.06% |
7,799
-2,240
| -22% | -$50.5K |
|
|
LONA
324
LeonaBio Inc
LONA
$65.5M
| $160K | 0.06% |
1,225
+129
| +12% | +$16.3K |
|
325
Instil Bio
TIL
$49.4M
| $160K | 0.06% |
+466
| New | +$180K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, Virtus ETF Advisers held 421 positions worth $265M, up 17% from $227M the previous quarter. Its ten largest holdings account for 9.2% of the portfolio.
Virtus ETF Advisers deployed $34M of net new capital in Q4 2021, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Invivyd: 22,625 shares worth $164K.
By sector, the portfolio is most concentrated in Real Estate at 22% of assets, up from 20% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Travere Therapeutics, an estimated $434K trimmed.
- Virtus ETF Advisers's largest Q4 2021 buy was Invivyd: 22,625 shares worth $164K.
- Virtus ETF Advisers added most to DT Midstream in Q4 2021, an estimated $1.85M increase.
- Virtus ETF Advisers's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $434K.
- Virtus ETF Advisers fully exited Coresite Realty Corporation in Q4 2021, selling an estimated $1.67M.
- Virtus ETF Advisers's ten largest holdings make up 9.2% of its $265M portfolio in Q4 2021.
- Virtus ETF Advisers opened 24 new positions and closed 45 in Q4 2021.
- Virtus ETF Advisers's portfolio value rose 17% quarter-over-quarter to $265M.
Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.